Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole vs Aripiprazole in Acute Schizophrenia
NCT02054702Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Feb 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of brexpiprazole orally disintegrating tablet in schizophrenia (2 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Positive and Negative Syndrome Scale Total Score at 6 weeks. Started Feb 2014; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02054702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02054702.